Teplizumab Approved to Delay Type 1 Diabetes Onset
Teplizumab (Tzield), a new FDA approved drug to delay the onset of type 1 diabetes (T1D) is indicated for children ages 8 and up with stage 2, T1D. Families with a history of T1D may ask for antibody screening. One option is to order “Islet Cell Antibody Screen” through the Cincinnati Children’s lab. The diabetes team is here to provide support and information about screening and interpretation. More information about Teplizumab, our recommendations for use, and lab testing updates will be available soon on the Cincinnati Children’s website. Feel free to contact Dr. Nicole Sheanon (nicole.sheanon@cchmc.org), with any additional questions.